About Nautilus
Nautilus is a biotechnology company founded in 2016 and based in Seattle, WA and San Carlos, CA.
Born from the founders’ recognition that their diverse but complementary skills and experiences could enable them to successfully address challenges that others had not, the company set about solving a vexing problem: how to bring true proteomics to the world in a way that accelerates therapeutic development, dramatically improves medical diagnostics, and advances the opportunity for personalized and predictive medicine.
The extraordinary team at Nautilus represents a wide spectrum of disciplines and expertise, including: protein chemists, chip designers, molecular biologists, data scientists, material scientists, biophysicists, optical engineers, microfluidics engineers, bioinformaticists, software engineers, and more.
At Nautilus, we firmly believe that audacious challenges can only be overcome by people and organizations that act boldly and with clear intention; thus, we are Pioneers, we are Risk Takers, and we act with Courage.
The Problem We Saw
We believe that the world is not well-served by the existing technologies available for broadscale proteomics. The current proteomics ecosystem is convoluted, onerous and does not allow for single molecule sensitivity. Proteomics has not evolved to deliver on the needs of the scientific and pharmaceutical R&D communities.
The Way We Are Solving It
With the goal of reimagining proteomics such that it can serve as the foundation for improving the health of millions of people across the globe, Nautilus’ first-generation platform is designed to deliver superior sensitivity more quickly, more completely, and less expensively than is currently possible. In doing so, we believe it will make possible the transformation of drug discovery, advance the potential of personalized/precision medicine, and expand the understanding of what’s possible for basic biological research.
The platform is the result of non-obvious and patent-protected science, and is based on the integration of a number of key disciplines:
Life Science
Physical Sciences & Engineering
Computer & Data Science
We believe that initial implementation of the platform will enable strategic partners and a range of other customers to dramatically decrease the time and cost required to undertake breakthrough drug development and related R&D initiatives. To discuss partnership opportunities, please contact us at partners@nautilus.bio.
The Team
Nautilus’ leadership team possesses an interdisciplinary combination of biology, chemistry, computer science, and business experience.
Sujal Patel
Parag Mallick, PhD
Anna Mowry
Nick Nelson
Subra Sankar
Matthew Murphy, Esq.
Chris Blessington
Mary Godwin
Founder & CEO
Sujal Patel
Sujal Patel is a successful technology entrepreneur and executive who founded and served as CEO of Isilon Systems, an enterprise data storage company. In 2006, Isilon completed one of the most successful initial public offerings of the year. Isilon was acquired by EMC in 2010 for $2.6 Billion, the largest acquisition in EMC’s history. Sujal served as the President of EMC’s Isilon Storage Division from the acquisition until 2012, driving significant revenue growth, market expansion and organizational scale. He graduated from the University of Maryland College Park in 1996 with a degree in Computer Science.
Founder & Chief Scientist
Parag Mallick, PhD
Dr. Parag Mallick is an Associate Professor at Stanford University, and an interdisciplinary scientist, who has developed multi-scale approaches to accelerate the discovery of diagnostic and prognostic protein biomarkers. Parag trained with pioneering researcher Ruedi Aebersold in clinical proteomics and systems biology at the Institute for Systems Biology. Parag holds a BS degree in Computer Science from Washington University in St. Louis, and a PhD in Chemistry & Biochemistry from UCLA. He has over 75 publications and holds patents in the fields of artificial intelligence, proteomics technology, biomarker development, and nanotechnology.
Chief Financial Officer
Anna Mowry
Anna is an experienced finance and business leader who joins Nautilus from Igneous where she served as VP of Finance and Operations with responsibility for finance, accounting, people, legal, and operations. Previously, Anna held a variety of roles at companies including Amazon Web Services and Isilon Systems, where she ultimately led the finance and sales operations organization. Anna has a BS in Biochemistry from Western Washington University and started her career at the Fred Hutchinson Cancer Research Institute. She earned her MBA from the University of Washington, leading her into a variety of finance and business roles of escalating responsibility.
Chief Business Officer
Nick Nelson
Nick Nelson has extensive leadership experience with top-tier diagnostics, therapeutics and life science companies. Before joining Nautilus, he was Chief Business Officer at Caris Life Sciences where he led all business development and strategic partnerships. Prior to Caris, he was Vice President of Commercial and Corporate Development at Trovagene (now Cardiff Oncology), and before that spent ten years at Illumina. While at Illumina he held leadership positions in the New and Emerging Markets business where he established partnerships and collaborations enabling high-growth genomics businesses. He received his Bachelor of Science degree in Cellular and Molecular Biology from San Diego State University.
SVP of Product Development
Subra Sankar
Subra is a seasoned product and engineering leader who joins Nautilus from GenapSys where he served as SVP of Product Development, leading the company’s R&D efforts including Engineering, Assay, System Integration, Consumable Development, Informatics and a variety of chemistry and molecular biology groups. Subra has held many senior roles over the last 15 years, notably at Solexa/Illumina where, from 2006 to 2012, he led instrument and consumable development efforts for next gen sequencers and related products. Subra has a Ph.D. in Aerospace Engineering from Georgia Tech and an MBA from UC Berkeley.
General Counsel
Matthew Murphy, Esq.
Matt has spent over a quarter century advising companies on the cutting edge of life sciences technologies. He has held numerous General Counsel roles over this period, including most notably at Pacific Biosciences and 10X Genomics. He specializes in creating and defending industry defining patent portfolios, and in building and leading legal operations that help develop, finance and commercialize high growth companies. Matt received his Bachelor of Science in Microbiology and Fermentation Science from the University of California, Davis, and a Juris Doctorate from the University of San Francisco School of Law.
VP of Corporate Marketing & Communications
Chris Blessington
Chris is a proven marketing leader who joins Nautilus from Smartsheet where he served as VP of Marketing and Communications with responsibility for creating markets, building awareness, and driving revenue. Prior to that, he led marketing and communications at ExtraHop Networks and Isilon Systems through the company’s acquisition by EMC. At EMC/Isilon, he served as executive sponsor of the company’s Life Sciences and Genomics markets, leading product evangelism, market research, and sales preparedness. Chris holds a BS from Syracuse University.
VP of Operations
Mary Godwin
Mary Godwin is a proven Operations and Supply Chain executive with deep experience across large corporations and smaller start ups. She brings to Nautilus deep experience developing processes and business relationships that improve both corporate metrics and financial performance. Before joining Nautilus, Mary held similar roles at Qumulo and Isilon Systems, where she built and scaled an operations function that supported over $1B in annual revenue. Prior experience included senior operational roles at Apple, Philips Electronics, and Lucent Technologies. She holds a Bachelor of Science degree in Plastics Engineering from the University of Massachusetts Lowell, and an MBA from Santa Clara University.
Ruedi Aebersold, PhD
Professor of Systems Biology
Institute of Molecular Systems Biology in ETH Zurich (IMSB)
- Pioneer in the field of proteomics
- Co-founder of several companies and head of the biology/disease branch of the human proteome project
Lee Hartwell, PhD
President and Director Emeritus
Fred Hutchinson Cancer Research Center
- Discovered protein molecules that control the division of cells
- 2001 Co-recipient Nobel Prize in Physiology and Medicine
Joshua LaBaer, MD, PhD
Executive Director
Biodesign Institute at Arizona State University
- Leading researcher in cancer and personalized medicine
- Inventor of the novel protein microarray technology, Nucleic Acid Programmable Protein Array (NAPPA), which has been used widely for biomedical research
Matthew Posard, Board Chair
Founding Principal, Explore DNA; Former SVP & Head of Sales, Illumina
Melissa Epperly
CFO, Zentalis Pharmaceuticals
Parag Mallick, PhD
Founder, Chief Scientist
Matt McIlwain
Managing Director, Madrona Venture Group
Stuart Nagae
Director, Vulcan Capital
Farzad Nazem
Angel Investor, Former EVP Engineering & CTO, Yahoo
Vijay Pande, PhD
General Partner, Andreessen Horowitz
Sujal Patel
Founder, Chief Executive Officer
Our Investors
